DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on May 30, 2008; DOI: 10.1124/dmd.107.019943

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.019943v1
36/9/1794    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brand, W.
Right arrow Articles by Rietjens, I. M.C.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brand, W.
Right arrow Articles by Rietjens, I. M.C.M.


Received for publication January 23, 2008.
Revised May 29, 2008.
Accepted for publication May 29, 2008.

Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers

Walter Brand 1*, Petronella A.I. van der Wel 1, Maarit J. Rein 2, Denis Barron 2, Gary Williamson 2, Peter J. van Bladeren 2, Ivonne M.C.M. Rietjens 1

1 Division of Toxicology, Wageningen University 2 Nestle Research Center

* Address correspondence to: E-mail: walter.brand{at}wur.nl

Abstract

Metabolism and transport from intestinal cells back into the lumen by ATP binding cassette (ABC) transporters is believed to limit the bioavailability of flavonoids. We studied metabolism and transport of the citrus flavonoid hesperetin, the aglycone of hesperidin, using a two-compartment transwell Caco-2 cell monolayer system, simulating the intestinal barrier. The role of apically located ABC transporters P-glycoprotein (Pgp/MDR1/ABCB1), Multidrug Resistance Protein 2 (MRP2/ABCC2) and Breast Cancer Resistance Protein (BCRP/ABCG2) in the efflux of hesperetin and its metabolites was studied by co-administration of compounds known to inhibit several classes of ABC transporters, including cyclosporin A, GF120918, Ko143, MK571, and PSC-833. Apically-applied hesperetin (10 µM) was metabolized into hesperetin 7-O-glucuronide and hesperetin 7-O-sulfate, identified using HPLC-DAD, uPLC-DAD-MS-MS and authentic standards, which were transported predominantly to the apical side of the Caco-2 cell monolayer (1.12 cm2), at average (SD) rates of 14.3 (3.7) pmol/min/monolayer and 2.1 (0.8) pmol/min/monolayer, respectively. Hesperetin aglycone also permeated to the basolateral side, and this process was unaffected by the inhibitors used, possibly implying a passive diffusion process. Inhibition studies, however, showed that efflux of hesperetin conjugates to the apical side involved active transport, which from the pattern of inhibition, appeared to involve mainly BCRP. Upon inhibition by the BCRP inhibitor Ko143 (5 µM), the apical efflux of hesperetin conjugates was 1.9-fold reduced (P≤0.01) and transport to the basolateral side was 3.1-fold increased (P≤0.001). These findings elucidate a novel pathway of hesperetin metabolism and transport, and show that BCRP-mediated transport could be a limiting step for hesperetin bioavailability.


Key words: ABC transporters, bioavailability, intestinal bioavailability, intestinal transport




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.